In vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma

被引:18
作者
D'Aloiso, L
Carlomagno, F
Bisceglia, M
Anaganti, S
Ferretti, E
Verrienti, A
Arturi, F
Scarpelli, D
Russo, D
Santoro, M
Filetti, S
机构
[1] Casa Sollievo Sofferenza Hosp, Unit Endocrinol, Inst Ric Cura Carattere Sci, I-71013 Foggia, Italy
[2] Casa Sollievo Sofferenza Hosp, Div Anat Pathol, Inst Ric Cura Carattere Sci, I-71013 Foggia, Italy
[3] Univ Naples Federico II, Ist Endocrinol Oncol Sperimentale, CNR, Dpto Biol Patol Cellulare Mol, I-80131 Naples, Italy
[4] Univ Roma La Sapienza, Dipartimento Sci Clin, I-00161 Rome, Italy
[5] Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy
[6] Univ Catanzaro Magna Graecia, Dipartimento Med Sperimentale & Clin Gaetano Salv, I-88100 Catanzaro, Italy
[7] Univ Catanzaro Magna Graecia, Dipartimento Sci Farmacobiol, I-88100 Catanzaro, Italy
关键词
D O I
10.1210/jc.2005-2338
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: RET mutation analysis provides useful information on the clinical outcome of medullary thyroid carcinomas (MTCs) and the risk of disease in the family members. Objective: The objective of this study was to document genotype-phenotype relationships in an Italian family with a novel RET mutation. Design/Setting: RET gene alterations were investigated in a patient with unifocal MTC and her relatives. The identified mutation was subjected to in vitro functional testing. Patients: Patients included a female proband who developed MTC at age 60, her five children, and three grandchildren. Main Outcome Measures: DNA extracted from the blood and the proband's tumor were analyzed for RET alterations. The transforming potential and mitogenic properties of the identified mutation were investigated. Results: A novel heterozygous germline RET mutation at codon 777 (AAC -> AGC, N -> S) (RET/N777S) was identified in the proband and three of her relatives. Two of the latter presented thyroid nodules, but none had MTC or C cell hyperplasia. The proband's MTC was characterized by late onset and limited aggressiveness, with no evidence of regional lymph node or distant metastases 10 yr after total thyroidectomy. This phenotype is consistent with the RET/N777S mutant's low-grade transforming potential and limited activation of RET tyrosine kinase. Conclusion: Our findings indicate that the newly identified RET/N777S mutation is a low-penetrant cause of MTC disease. This phenotype might be less aggressive than that associated with MEN2A of familial MTC, although close clinical follow-up of carriers is essential.
引用
收藏
页码:754 / 759
页数:6
相关论文
共 17 条
  • [1] Carlomagno F, 1997, CANCER RES, V57, P391
  • [2] Molecular heterogeneity of RET loss of function in Hirschsprung's disease
    Carlomagno, F
    DeVita, G
    Berlingieri, MT
    deFranciscis, V
    Melillo, RM
    Colantuoni, V
    Kraus, MH
    DiFiore, PP
    Fusco, A
    Santoro, M
    [J]. EMBO JOURNAL, 1996, 15 (11) : 2717 - 2725
  • [3] RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population
    Elisei, R
    Cosci, B
    Romei, C
    Bottici, V
    Sculli, M
    Lari, R
    Barale, R
    Pacini, F
    Pinchera, A
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (07) : 3579 - 3584
  • [4] The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 - International RET mutation consortium analysis
    Eng, C
    Clayton, D
    Schuffenecker, I
    Lenoir, G
    Cote, G
    Gagel, RF
    vanAmstel, HKP
    Lips, CJM
    Nishisho, I
    Takai, SI
    Marsh, DJ
    Robinson, BG
    FrankRaue, K
    Raue, F
    Xue, FY
    Noll, WW
    Romei, C
    Pacini, F
    Fink, M
    Niederle, B
    Zedenius, J
    Nordenskjold, M
    Komminoth, P
    Hendy, GN
    Gharib, H
    Thibodeau, SN
    Lacroix, A
    Frilling, A
    Ponder, BAJ
    Mulligan, LM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (19): : 1575 - 1579
  • [5] A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma
    Jimenez, C
    Dang, GT
    Schultz, PN
    El-Naggar, A
    Shapiro, S
    Barnes, EA
    Evans, DB
    Vassilopoulou-Sellin, R
    Gagel, RF
    Cote, GJ
    Hoff, AO
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (07) : 3521 - 3526
  • [6] Medullary thyroid carcinoma
    Leboulleux, S
    Baudin, E
    Travagli, JP
    Schlumberger, M
    [J]. CLINICAL ENDOCRINOLOGY, 2004, 61 (03) : 299 - 310
  • [7] Germline homozygous mutations at codon 804 in the RET protooncogene in medullary thyroid carcinoma/multiple endocrine neoplasia type 2A patients
    Lesueur, F
    Cebrian, A
    Cranston, A
    Leyland, J
    Faid, TM
    Clements, MR
    Robledo, M
    Whittaker, J
    Ponder, BAJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (06) : 3454 - 3457
  • [8] Familial medullary thyroid carcinoma:: Clinical variability and low aggressiveness associated with RET mutation at codon 804
    Lombardo, F
    Baudin, E
    Chiefari, E
    Arturi, F
    Bardet, S
    Caillou, B
    Conte, C
    Dallapiccola, B
    Giuffrida, D
    Bidart, JM
    Schlumberger, M
    Filetti, S
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (04) : 1674 - 1680
  • [9] The RET receptor:: function in development and dysfunction in congenital malformation
    Manié, S
    Santoro, M
    Fusco, A
    Billaud, M
    [J]. TRENDS IN GENETICS, 2001, 17 (10) : 580 - 589
  • [10] Diagnosis and management of medullary thyroid carcinoma
    Massoll, N
    Mazzaferri, EL
    [J]. CLINICS IN LABORATORY MEDICINE, 2004, 24 (01) : 49 - +